Latest news with #AlexCunningham
Associated Press
20-05-2025
- Business
- Associated Press
Cardiff Lexington Announces Uplisting to OTCQB Venture Market
LEXINGTON, KY / ACCESS Newswire / May 20, 2025 / Cardiff Lexington Corporation (OTCQB:CDIX) today announced that the Company's stock has successfully uplisted and commenced trading on the OTCQB Venture Market (the 'OTCQB'), effective Thursday, May 15, 2025. The Company will continue to trade under the ticker symbol 'CDIX.' This uplisting was achieved following a successful application and approval process to verify that Cardiff Lexington meets OTCQB listing qualifications. Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commented, 'Uplisting to the OTCQB Venture Market represents a significant milestone for our Company and reflects our commitment to transparency, growth, and delivering long-term value to our shareholders. We have made considerable progress expanding our business and putting Cardiff Lexington on track for a record 2025 while also significantly streamlining our capital structure. This achievement enhances our visibility with investors and supports our continued momentum as we move through 2025 and beyond.' The OTCQB, operated by OTC Markets Group and recognized by the U.S. Securities and Exchange Commission (SEC) as a reputable public market for early stage and developing U.S. and internal companies, offers investors essential data to evaluate, value, and trade securities. Cardiff Lexington's inclusion in the OTC Markets Group is expected to support the expansion and diversification of its global shareholder base. ----- About Cardiff Lexington Corporation: Cardiff Lexington Corporation is a unique targeted healthcare holding company focused on locating, acquiring, and building middle market, niche companies, primarily in Orthopedics, Spine Care, and Pain Management. Fundamental to the Cardiff Lexington strategy is the service-based partnership culture which emphasizes core values, teamwork, accountability, and performance. A substantial majority of the Company's revenue is derived from Nova Ortho and Spine, LLC, which operates a group of regional primary specialty and ancillary care facilities throughout Florida and Georgia that provide traumatic injury victims with a full range of diagnostic and surgical services, primary care evaluations, interventional pain management, and specialty consultation services. Cardiff Lexington trades on the OTCQB Venture Market for early stage and developing U.S. and international companies. Companies are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information for the company on For more information on Cardiff Lexington Corporation, you may access the company's website at FORWARD-LOOKING STATEMENT: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's business, the Company's liquidity position, the Company's ability to obtain new business, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur. Cardiff Lexington Investor Relations [email protected] (800) 628-2100 ext. 705 or IMS Investor Relations [email protected] (203) 972-9200 SOURCE: Cardiff Lexington Corporation press release
Associated Press
13-05-2025
- Business
- Associated Press
Cardiff Lexington Announces First Quarter 2025 Financial Results
LEXINGTON, KY / ACCESS Newswire / May 13, 2025 / Cardiff Lexington Corporation (OTC PINK:CDIX) announced today financial results for its first quarter ended March 31, 2025. Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commented, 'Our first quarter results were characterized by strong year-over-year growth in revenue, gross profit, and operating margin, as well as an increase in non-GAAP adjusted EBITDA compared to the prior year. Demand for our services is strong and patient volume is steadily improving. In 2024, we opened several new Nova Ortho and Spine locations in key population centers throughout Florida and the southeast US, and we are now seeing the benefits of this expansion. We believe that we are well positioned to achieve record revenues in 2025.' First Quarter 2025 Financial Results (Compared to First Quarter 2024) Balance Sheet (March 31, 2025, compared to December 31, 2024) Alex Cunningham continued, 'Since the beginning of the year, we have significantly streamlined our capital structure through the ongoing conversion of long-standing preferred shares to common stock. This provides us with a transformed cap table to better support the anticipated growth in our business while also enabling higher trading volume in our shares over time.' ----- About Cardiff Lexington Corporation: Cardiff Lexington Corporation is a unique targeted healthcare holding company focused on locating, acquiring, and building middle market, niche companies, primarily in Orthopedics, Spine Care, and Pain Management. Fundamental to the Cardiff Lexington strategy is the service-based partnership culture which emphasizes core values, teamwork, accountability, and performance. A substantial majority of the Company's revenue is derived from Nova Ortho and Spine, LLC, which operates a group of regional primary specialty and ancillary care facilities throughout Florida and Georgia that provide traumatic injury victims with a full range of diagnostic and surgical services, primary care evaluations, interventional pain management, and specialty consultation services. For more information on Cardiff Lexington Corporation, you may access the company's website at FORWARD LOOKING STATEMENT: This news release contains forward looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's business, the Company's liquidity position, the Company's ability to obtain new business, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur. Use of Non-GAAP Financial Measures Cardiff Lexington Corporation prepares its consolidated financial statements in accordance with United States generally accepted accounting principles ('GAAP'). In addition to GAAP disclosures, this document contains financial information and measures considered to be 'non-GAAP'. These non-GAAP measures can be used in order to gain a more complete and accurate understanding of the Company's financial condition and results. Non-GAAP financial measures should be considered in conjunction with, and not as a substitute to GAAP financial measures. Cardiff Lexington Investor Relations [email protected] (800) 628-2100 ext. 705 or IMS Investor Relations [email protected] (203) 972-9200 CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2024 AND 2023 (Unaudited) CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2024 AND DECEMBER 31, 2023 (Unaudited) CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES RECONCILIATION OF NON-GAAP FINANCIAL MEASURES FOR THE THREE AND TWELVE MONTHS ENDED DECMBER 31, 2024 AND 2023 (Unaudited) The following table reconciles Net (loss) income before discontinued operations (a GAAP measure) to EBITDA (a non-GAAP measure) CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES RECONCILIATION OF REVENUE FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2024 (Unaudited) SOURCE: Cardiff Lexington Corporation press release
BBC News
22-04-2025
- Health
- BBC News
Call for Teesside hospital trust leadership review rejected
A call for a full leadership review at Teesside's two hospital trusts has been rejected by NHS follows the regulatory body's 2022 probe into attempts to find a new CEO to lead both South Tees Hospitals NHS Foundation Trust and North Tees and Hartlepool NHS Foundation Trust (NTH).A subsequent report spawned a lengthy legal battle to get a number of redactions removed, with some claiming the resulting new information warranted a change at the an NHS England spokesperson has said University Hospitals Tees - a strategic alliance since formed by the two trusts - is "in the best interests of patients and services". In a letter sent to Health Secretary Wes Streeting earlier this year, former Stockton North MP Alex Cunningham and ex-NTH chief executive Julie Gillon also criticised an ensuing "deterioration of services and staff morale". Signed by other former non-executive directors from NTH, it said that the trust had been "one of the best performers in the country - but sadly no more". "The recent national staff survey paints a disappointing picture of worsening morale, and performance data suggests that improvement has stalled or declined." But University Hospital Tees CEO Stacey Hunter disputed the claim services had deteriorated at NTH and said its urgent and emergency care was ranked among the best in the region."In common with all trusts across England, NTH is making good progress on reducing waiting times, as we continue our elective recovery from the impact of the Covid-19 pandemic," she said."The NHS staff survey saw us score highly in staff morale, staff engagement, compassion and inclusivity."We value the fact that colleagues make their voices heard."Their openness and honesty helps us to make the right changes to how our group operates." A regional spokesman for NHS England, which had prompted the trusts' changes and is responsible for managing the NHS in England, said: "Greater co-operation between North and South Tees is in the best interests of patients and supports the sustainability and safety of services."It is being progressed through good local leadership." Follow BBC Tees on X, Facebook, Nextdoor and Instagram.
BBC News
07-04-2025
- Business
- BBC News
Teesworks will not appeal against High Court port ruling
The UK's biggest freeport has dropped an appeal against a High Court ruling, which ordered it to pay millions of pounds in year, the court ruled PD Ports had the right to access land at the Teesworks redevelopment site in case was brought by Teesworks and the South Tees Development Corporation (STDC), which were ordered to pay the port's court costs, estimated at £ initially planned to appeal against the ruling but has confirmed to the Local Democracy Reporting Service the appeal had been withdrawn and discontinued. Following the six-week trial, Mr Justice Rajah ruled in PD Ports' favour on six out of 18 claims under said the court case was needed to provide clarity on what access rights PD Ports had to the the time, Labour MP for Stockton North Alex Cunningham criticised the decision to pursue the "meaningless action" which he said landed the public with a "massive legal bill". PD Ports, which operates Teesport, said the Court of Appeal largely refused Teesworks permission to appeal, except on pedestrian access along South Gare said it had never intended to appeal against the High Court ruling, which it again confirmed during a recent board Valley Mayor Ben Houchen said: "Just to be clear from an STDC point of view, there's no additional financial liability at all on what Teesworks decide to do themselves. "But I believe that legal action's been discontinued." Follow BBC Tees on X, Facebook, Nextdoor and Instagram.
